3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
By developing compounds with IKZF2 degradation activity, the toxicity problem caused by T effector cell activation in existing anti-CTLA4 treatment methods is solved, and specific targeting and immune response enhancement of Treg in tumors is achieved, providing a safer and effective cancer treatment methods.
Patent Information
- Application Number
- CN202080014181.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-02-15
- Filing Date
- 2020-02-13
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-02-13
AI Technical Summary
Existing anti-CTLA4 treatments often cause systemic activation of T effector cells when targeting tumors, resulting in excessive toxicity and limited therapeutic utility, and lack of compounds that can specifically target Treg without activate T effector cells.
Developing compounds with IKZF2 degradation activity, especially 3-(1-oxo-5-(piperidin-4-yl)isoindoline-2-yl)piperidin-2,6-dione compounds and combinations thereof , used to reduce IKZF2 levels in Treg in tumors, thereby enhancing the targeting and tolerance of the immune response.
By reducing IKZF2 levels, compounds can enable the immune system to attack tumors more effectively, providing a less toxic and more tolerant treatment regimen that enhances the immune response to tumors.
Smart Images

Figure CN113490528B_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 62 / 806,140, filed February 15, 2019, the entire contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione compounds and compositions and their use for treating IKAROS family zinc finger 2 (IKZF2)-dependent diseases or disorders or where reducing IKZF2 or IKZF4 protein levels can alleviate the disease or disorder. Background Art
[0004] IKAROS family zinc finger 2 (IKZF2) (also known as Helios) is one of five members of the Ikaros family of transcription factors found in mammals. IKZF2 contains four zinc finger domains near the N-terminus, which are involved in DNA binding, and two zinc finger domains at the C-terminus, which are involved in protein dimerization. IKZF2 shares approximately 50% identity with the Ikaros family members Ikaros (IKZF1), Aiolos (IKZF3), and Eos (IKZF4), with the highest homology (80%+ identity) in the zinc finger region. These four Ikaros family transcription factors bind to the same consensus DNA site and can heterodimerize with each other when co-expressed in cells. The fifth Ikaros family protein, Pegasus (IKZF5), shares only 25% identity with IKZF2, binds to a different DNA site than the other Ikaros family members, and is less likely to heterodimerize with other Ikaros family proteins. IKZF2, IKZF1, and IKZF3 are primarily expressed in hematopoietic cells, whereas IKZF4 and IKZF5 are expressed in a variety of tissues (John, LB, et al. (2011), Mol. Immunol. 48:1272-1278; Perdomo, J., et al. (2000), J. Biol. Chem. 275:38347-38354).
[0005] It is believed that IKZF2 plays an important role in the function and stability of regulatory T cells (Treg). IKZF2 is highly expressed at the mRNA and protein levels by regulatory T cell populations. It has been shown that knocking down IKZF2 by siRNA leads to the downregulation of FoxP3 and damages the ability of isolated human CD4+CD25+Treg to block T cell activation in vitro. In addition, it has been shown that overexpression of IKZF2 in isolated mouse Treg increases the expression of Treg-related markers such as CD103 and GITR, and cells overexpressing IKZF2 show increased suppression of responding T cells. It has also been found that IKZF2 binds to the promoter of FoxP3 (a defining transcription factor of the regulatory T cell lineage) and affects FoxP3 expression.
[0006] It has been shown that knockout of IKZF2 within FoxP3-expressing Tregs in mice causes activated Tregs to lose their suppressive properties, express T-effector cytokines, and assume T-effector functions. IKZF2 knockout mutant mice develop autoimmune disease at 6-8 months of age, with increased numbers of activated CD4 and CD8 T cells, follicular helper T cells, and germinal center B cells. This observed effect is thought to be cell-intrinsic, as Rag2- / - mice given bone marrow from IKZF2 knockout mice, but not from IKZF2+ / + mice, develop autoimmune disease. Direct evidence that IKZF2 influences regulatory T cell function has been shown in analyses of mice in which IKZF2 is deleted exclusively in FoxP3-expressing cells (FoxP3-YFP-CreHeliosfl / fl). The results showed that the mice also develop autoimmune disease with similar features to those observed in whole-animal IKZF2 knockout. In addition, pathway analysis of the CHIP-seq experiment also showed that IKZF2 affects the expression of genes in the STAT5 / IL-2Rα pathway in regulatory T cells. This effect of IKZF2 loss was more pronounced after immune challenge (viral infection or injection with sheep blood), and it was noted that after immune stimulation, IKZF2 negative regulatory T cells began to take on the characteristics of effector T cells. (Getnet, D. et al., Mol. Immunol. [Molecular Immunology] (2010), 47: 1595-1600; Bin Dhuban, K. et al., (2015), J. Immunol. [Journal of Immunology] 194: 3687-96; Kim, H. J. et al., (2015), Science [Science] 350: 334-339; Nakawaga, H. et al., (2016) PNAS [Proceedings of the National Academy of Sciences of the United States of America], 113: 6248-6253)
[0007] Overexpression of Ikaros isoforms lacking a DNA binding region has been shown to be associated with a variety of human hematological malignancies. Recently, mutations in the IKZF2 gene that cause abnormal splicing variants have been identified in adult T-cell leukemia and low hypodiploid acute lymphoblastic leukemia. It has been proposed that these isoforms capable of dimerization have a dominant negative effect on the Ikaros family transcription factors that cause lymphoma development. IKZF2 knockout mutants that survive to adulthood do not develop lymphomas, which supports this hypothesis (Asanuma, S. et al., (2013), Cancer Sci. [Cancer Science] 104: 1097-1106; Zhang, Z. et al., (2007), Blood [Blood] 109: 2190-2197; Kataoka, D. et al., (2015), Nature Genetics [Natural Genetics] 47: 1304-1315).
[0008] Currently, anti-CTLA4 antibodies are used clinically to target Tregs in tumors. However, targeting CTLA4 often causes systemic activation of T effector cells, leading to excessive toxicity and limiting therapeutic utility. Up to three-quarters of patients treated with a combination of anti-PD-1 and anti-CTLA4 reported grade 3 or higher adverse events. Therefore, there is a strong need to provide compounds that target Tregs in tumors without causing systemic activation of T effector cells.
[0009] IKZF2-specific degraders have the potential to focus enhanced immune responses to areas within or near tumors, providing potentially more tolerable and less toxic therapeutics for the treatment of cancer. Summary of the Invention
[0010] The compounds disclosed herein have uses as therapeutic agents, particularly for cancer and related diseases. In one aspect, the compounds disclosed herein have IKZF2 degradation activity, preferably having activity equal to or less than 50 μM, and more preferably having activity equal to or less than 10 μM. In another aspect, the compounds disclosed herein have degradation activity against IKZF2, and the degradation activity is selective for one or more of IKZF1, IKZF3, IKZF4, and / or IKZF5. In another aspect, the compounds disclosed herein have degradation activity against both IKZF2 and IKZF4. The compounds disclosed herein are useful in treating cancer and other diseases in which such degradation activity is beneficial to patients. For example, while not intending to be bound by any theory, the inventors believe that reducing the level of IKZF2 in Tregs in tumors can enable the patient's immune system to more effectively attack the disease. In summary, the present disclosure provides novel IKZF2 degraders for the treatment of cancer and other diseases.
[0011] The first aspect of the present disclosure relates to compounds having formula (I)
[0012]
[0013] in:
[0014] R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH or CN;
[0015] Each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, CN, or halogen, or
[0016] R1 and R2 together with the carbon atoms to which they are attached form a (C3-C7)cycloalkyl or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, or
[0017] Two R2 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S;
[0018] R3 is (C1-C6) alkyl, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, or a 4- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one or more R4; and the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R5, or
[0019] When on adjacent atoms, R2 and R3, together with the atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring;
[0020] Each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6' 、Halogen、-OH、-NH2、CN、(C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one or more R7;
[0021] Each R5 is independently selected from (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -NH2, CN, (C3-C7) cycloalkyl, 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or
[0022] When on adjacent atoms, the two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally replaced by one or more R 10 Replace, or
[0023] Two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or more R 10 replace;
[0024] R6 and R 6' are each independently H, (C1-C6) alkyl, or (C6-C 10 ) aryl;
[0025] Each R7 is independently selected from (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -C(O)R8, -(CH2) 0-3 C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10) aryl, adamantyl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, (C6-C 10 )aryl, a monocyclic or bicyclic 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one or more R 11 substituted, and the aryl, heteroaryl, and heterocycloalkyl are optionally substituted by one or more substituents each independently selected from the group consisting of halogen, (C1-C6) alkyl, (C1-C6) haloalkyl, and (C1-C6) alkoxy, or
[0026] Two R7 together with the carbon atom to which they are attached form a=(O), or
[0027] When on adjacent atoms, the two R7 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally replaced by one or more R 10 Replace, or
[0028] Two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or more R 10 replace;
[0029] R8 and R9 are each independently H or (C1-C6) alkyl;
[0030] Each R 10 independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN, or
[0031] Two R's 10 Together with the carbon atom to which they are attached, they form a=(O);
[0032] Each R 11 Independently selected from CN, (C1-C6) alkoxy, (C6-C 10)aryl, and a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heterocycloalkyl groups are optionally substituted with one or more substituents each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN;
[0033] R 12 (C1-C6) alkyl, (C1-C6) haloalkyl, (C6-C 10 ) aryl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S;
[0034] R x is H or D; and
[0035] n is 0, 1, 2, or 3;
[0036] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
[0037] In one aspect of the present disclosure, the hydrogen in the compound of formula (I) is present in its normal isotopic abundance. In a preferred aspect of the present disclosure, the hydrogen isotopically enriched in deuterium (D), and in a particularly preferred aspect of the present invention, position R x The hydrogen enrichment D is discussed in more detail below with respect to isotopes and isotopic enrichment.
[0038] In another aspect, the disclosure relates to a compound selected from the group consisting of:
[0039]
[0040]
[0041]
[0042] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
[0043] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is useful in treating an IKZF2-dependent disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0044] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder. The pharmaceutical composition is useful in treating an IKZF2-dependent disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0045] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is useful in treating a disease or disorder affected by a decrease in IKZF2 protein levels. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0046] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient for use in treating a disease or disorder affected by reduced IKZF2 protein levels, wherein the reduced IKZF2 protein levels treat the disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0047] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-19), (I-20), (I-21), (I-22), (I-23), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-35), (I-36), (I-37), (I-38), (I-39), (I-40), (I-41), (I-42), (I-43), (I-44), (I-45), (I-46), (I-47), (I-48), (I-49), (I-50), (I-51), (I-52), (I-53), (I-54), (I-55), (I-56), (I-57), (I-58), (I-59), (I-60), (I-61), (I-62), (I-63), (I-64), (I-65), (I-66), (I-67), (I-68), (I-69), (I-70), (I-71), (I-72), (I-73), (I-74), (I-75), (I-76), (I-77), (I-78), (I-79), (I-80), (I-81), (I-82), (I-83 -11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). The pharmaceutical composition is useful in treating IKZF2-dependent diseases or disorders. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0048] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5) , (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). The pharmaceutical composition is useful in treating an IKZF2-dependent disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0049] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-19), (I-20), (I-21), (I-22), (I-23), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-35), (I-36), (I-37), (I-38), (I-39), (I-40), (I-41), (I-42), (I-43), (I-44), (I-45), (I-46), (I-47), (I-48), (I-49), (I-50), (I-51), (I-52), (I-53), (I-54), (I-55), (I-56), (I-57), (I-58), (I-59), (I-60), (I-61), (I-62), (I-63), (I-64), (I-65), (I-66), (I-67), (I-68), (I-69), (I-70), (I-71), (I-72), (I-73), (I-74), (I-75), (I-76), (I-77), (I-78), (I-79), (I-80), (I-81), (I-82), (I-83 -11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). The pharmaceutical composition is useful in treating a disease or disorder affected by a decrease in IKZF2 protein levels. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0050] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient, for use in treating a disease or disorder affected by reduced IKZF2 protein levels, wherein reduced IKZF2 protein levels treat the disease or disorder, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25 ), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0051] Another aspect of the present disclosure relates to a method of degrading IKZF2, comprising administering to a patient in need thereof a compound having formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0052] In another aspect, the disclosure relates to a method of treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising administering to a patient in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0053] Another aspect of the disclosure relates to a method of modulating IKZF2 protein levels, comprising administering to a patient in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0054] In another aspect, the disclosure relates to a method of reducing proliferation of a cell, comprising contacting the cell with a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and reducing IKZF2 protein levels.
[0055] Another aspect of the present disclosure relates to a method for treating cancer, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, a hydrate, a solvate, a prodrug, a stereoisomer, or a tautomer to a patient in need thereof. In one embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is a cancer or immunogenic cancer of an immune response defect.
[0056] In another aspect, the disclosure relates to a method for reducing IKZF2 protein levels in a subject, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having formula (I), or a pharmaceutically acceptable salt thereof.
[0057] Another aspect of the disclosure relates to a compound having formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased levels of IKZF2 protein.
[0058] In another aspect, the disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by decreased IKZF2 protein levels.
[0059] Another aspect of the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with a reduction in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
[0060] In another aspect, the present disclosure relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
[0061] Another aspect of the present disclosure relates to a method for degrading IKZF2, comprising administering to a patient in need thereof a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is selected from the group consisting of compounds (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0062] In another aspect, the present disclosure relates to a method for treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising administering to a patient in need thereof a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10) , (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I- 27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0063] Another aspect of the present disclosure relates to a method for regulating IKZF2 protein levels, comprising administering to a patient in need thereof a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11 ), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27) , (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0064] In another aspect, the disclosure relates to a method for reducing proliferation of a cell, comprising contacting the cell with a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and reducing IKZF2 protein levels, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-2 7), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0065] Another aspect of the present disclosure relates to a method for treating cancer, comprising administering to a patient in need thereof a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). In one embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is an immune response defective cancer or an immunogenic cancer.
[0066] In another aspect, the disclosure relates to a method for reducing the level of IKZF2 protein in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of compounds (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0067] Another aspect of the present disclosure relates to a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased IKZF2 protein levels, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11 ), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27) , (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0068] In another aspect, the present disclosure relates to the use of a compound selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-19), (I-20), (I-21), (I-22), (I-23), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-35), (I-36), (I-37), (I-38), (I-39), (I-40), (I-41), ( -11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27 ), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0069] Another aspect of the present disclosure relates to a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with decreased IKZF2 protein levels, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-19), (I-20), (I-21), (I-22), (I-23), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I- In one embodiment, the disease or disorder is selected from the group consisting of non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
[0070] In another aspect, the present disclosure relates to a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder associated with decreased IKZF2 protein levels, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11) , (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38). In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
[0071] In another aspect of the present disclosure, the compound according to the present disclosure is formulated into a pharmaceutical composition comprising an effective amount, preferably a pharmaceutically effective amount, of the compound according to the present disclosure or a salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable excipient or carrier.
[0072] In some embodiments of the methods disclosed herein, administration of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof is performed orally, parenterally, subcutaneously, by injection, or by infusion.
[0073] In some embodiments of the methods disclosed herein, the compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, is administered orally, parenterally, subcutaneously, by injection, or by infusion, wherein the compound is selected from compound (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-19), (I-20), (I-21), (I-22), (I-23), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), ( -11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27 ), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38).
[0074] The present disclosure provides degraders of IKZF2 that are therapeutic agents in treating diseases such as cancer and metastasis, in treating diseases affected by modulation of IKZF2 protein levels, and in treating IKZF2-dependent diseases or disorders.
[0075] In one embodiment, the disease or disorder that can be treated by the compounds of the present disclosure is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, soft tissue sarcoma, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In another embodiment, the IKZF2-dependent disease or disorder is a cancer with a defective immune response or an immunogenic cancer.
[0076] The present disclosure provides agents with novel mechanisms of action for IKZF2 proteins in the treatment of different types of diseases, including cancer and metastasis, in the treatment of diseases affected by modulation of IKZF2 protein levels, and in the treatment of IKZF2-dependent diseases or disorders. Ultimately, the present disclosure provides the medical community with novel pharmacological strategies for treating diseases and disorders associated with the IKZF2 protein.
[0077] The present disclosure provides agents with novel mechanisms of action for IKZF2 proteins in the treatment of different types of diseases, including cancer and metastasis, in the treatment of diseases affected by modulation of IKZF2 protein levels, and in the treatment of IKZF2-dependent diseases or disorders. Ultimately, the present disclosure provides the medical community with novel pharmacological strategies for treating diseases and disorders associated with the IKZF2 protein. DETAILED DESCRIPTION
[0078] The present disclosure relates to compounds and compositions capable of modulating IKZF2 protein levels. The present disclosure features methods for treating, preventing, or alleviating a disease or disorder, wherein IKZF2 is exerted by administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to a patient in need thereof. The methods of the present disclosure can be used to treat various IKZF2-dependent diseases and disorders by modulating IKZF2 protein levels. Modulating IKZF2 protein levels through degradation provides a novel approach for treating, preventing, or alleviating diseases (including, but not limited to, cancer and metathesis) and other IKZF2-dependent diseases or disorders.
[0079] In one aspect, the compounds disclosed herein have uses as therapeutic agents, particularly for cancer and related diseases. In one aspect, the compounds disclosed herein have IKZF2 degradation activity, preferably having activity equal to or less than 50 μM, and more preferably having activity equal to or less than 10 μM. In another aspect, the compounds disclosed herein have degradation activity against IKZF2, and the degradation activity is selective for one or more of IKZF1, IKZF3, IKZF4, and / or IKZF5. In another aspect, the compounds disclosed herein have degradation activity against both IKZF2 and IKZF4. The compounds disclosed herein are useful in treating cancer and other diseases in which such degradation activity is beneficial to patients. For example, while not intending to be bound by any theory, the inventors believe that reducing the level of IKZF2 in Tregs in tumors can enable the patient's immune system to more effectively attack the disease. In summary, the present disclosure provides novel IKZF2 degraders for the treatment of cancer and other diseases.
[0080] In a first aspect of the present disclosure, compounds having formula (I) are described:
[0081]
[0082] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof, wherein R1, R2, R3, R x , and n are as described above.
[0083] The details of the present disclosure are set forth in the specification sheet attached below. Although methods and materials similar or equivalent to those described herein can be used for the practice or testing of the present disclosure, illustrative methods and materials are now described. According to the specification sheet and according to the claims, other features, objects and advantages of the present disclosure will be clear. In this specification sheet and the appended claims, the singular form also includes the plural form, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present disclosure belongs. All patents and public documents cited in this specification sheet are incorporated herein by reference in their entirety.
[0084] Definitions of terms and conventions used
[0085] Terms that are not explicitly defined herein should be understood to have the meanings that would be derived by those skilled in the art based on this disclosure and the context. However, unless otherwise indicated, the following terms as used in this specification and the appended claims have the indicated meanings and adhere to the following conventions.
[0086] A. Chemical Nomenclature, Terminology, and Conventions
[0087] In the groups, radicals or moieties defined below, the number of carbon atoms is usually indicated before the radical, e.g. (C1-C 10 ) alkyl means an alkyl group with 1 to 10 carbon atoms. Generally speaking, for a group comprising two or more subgroups, the last group mentioned is a group connection point, for example, "alkylaryl" means a monovalent group of the formula alkyl-aryl-, and "arylalkyl" means a monovalent group of the formula aryl-alkyl-. In addition, the term "a" is used to represent a monovalent group and wherein a divalent group is suitable, it is understood to represent a corresponding divalent group, and vice versa. Unless otherwise stated, the conventional definition of the term contrast and the atomic valence of conventional stable atoms are assumed and embodied in all formulas and groups. The article "a / an" refers to the grammatical object of one / kind or more than one / kind (e.g., at least one / kind) of the article. By way of example, "an element" means one element or more than one element.
[0088] Unless otherwise indicated, the term "and / or" means "and" or "or".
[0089] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents other than hydrogen. For example, it can be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein at any position along the chain. Thus, the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any other functional groups. Suitable substituents for optional substitution of the groups include, but are not limited to, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH )2, -OC(O)(C1-C6)alkyl, -C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -NHC(O)(C1-C6)alkyl, -C(O)NH(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and S(O)N((C1-C6)alkyl)2. The substituents themselves may be optionally substituted. As used herein, "optionally substituted" also refers to substituted or unsubstituted, the meaning of which is described below.
[0090] The term "substituted" means that the specified group or moiety bears one or more suitable substituents, wherein the substituents may be attached to the specified group or moiety at one or more positions. For example, an aryl group substituted with a cycloalkyl group may indicate that the cycloalkyl group is attached to an atom of the aryl group by a bond or by being fused to the aryl group and sharing two or more common atoms.
[0091] The term "unsubstituted" means that the specified group has no substituents.
[0092] Unless otherwise specifically defined, "aryl" means a cyclic aromatic hydrocarbon group having 1 to 3 aromatic rings (including monocyclic or bicyclic groups), such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group are optionally connected at a single point (e.g., biphenyl) or fused (e.g., naphthyl). The aryl group is optionally substituted with one or more substituents at any point of attachment, for example, 1 to 5 substituents. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(C-C)alkyl, (C-C)alkyl, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(C-C)alkyl, -C(O)(C-C)alkyl, -OC(O)O(C-C)alkyl, NH2, NH((C-C)alkyl), N((C-C)alkyl)2, -S(O)2-(C-C)alkyl, -S(O)NH(C-C)alkyl, and S(O)N((C-C)alkyl)2. The substituents themselves are optionally substituted. In addition, when containing two fused rings, the aryl group optionally has an unsaturated or partially saturated ring fused to the fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthyl, tetrahydrobenzoannulyl, etc.
[0093] Unless otherwise expressly defined, "heteroaryl" means a monovalent monocyclic aromatic group or polycyclic aromatic group of 5 to 24 ring atoms containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C. Heteroaryl as defined herein also means a bicyclic heteroaromatic group wherein the heteroatoms are selected from N, O, or S. Aromatic groups are optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thien-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1, 2-b]pyrazolyl, fluoro[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl , indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzooxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzooxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine ...thiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydro Azo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1Δ 2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, fluoro[3,2-c]pyridinyl, fluoro[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, fluoro[2,3-b]pyridinyl, benzophenylthio, 1,5-naphthyridinyl, fluoro[3,2-b]pyridine, [1,2,4]triazolo[l,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4] Triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. In addition, when containing two fused rings, the aryl groups defined herein may have an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzooxanyl.
[0094] Halogen or "halo" means fluorine, chlorine, bromine, or iodine.
[0095] "Alkyl" means a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms. Examples of (C1-C6)alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
[0096] "Alkoxy" means a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms, which contains a terminal "O" in the chain, such as -O(alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, or pentoxy groups.
[0097] "Alkenyl" means a straight or branched unsaturated hydrocarbon containing 2-12 carbon atoms. An "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted and can be straight or branched.
[0098] "Alkynyl" means a straight or branched unsaturated hydrocarbon containing 2-12 carbon atoms. An "alkynyl" group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, isobutynyl, pentynyl, or hexynyl. Alkynyl groups can be unsubstituted or substituted.
[0099] "Alkylene" or "alkylenyl" means a divalent alkyl group. Any of the above monovalent alkyl groups can be converted to an alkylene group by extracting a second hydrogen atom from the alkyl group. As defined herein, an alkylene group can also be a (C1-C6)alkylene group. An alkylene group can further be a (C1-C4)alkylene group. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH-, and the like.
[0100] "Cycloalkyl" or "carbocyclyl" means a monocyclic or polycyclic saturated or partially unsaturated non-aromatic carbocyclic ring containing 3-18 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norboranyl, norborenyl, bicyclo[2.2.2]octyl, or bicyclo[2.2.2]octenyl and derivatives thereof. (C3-C8)cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. Cycloalkyl groups can be fused (e.g., decalin) or bridged (e.g., norbornane).
[0101] "Heterocyclyl" or "heterocycloalkyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen or sulfur (O, N or S), and wherein there is no shared non-localized n electron (aromaticity) between the ring carbons or heteroatoms. The heterocycloalkyl ring structure may be substituted with one or more substituents. The substituents themselves may be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetane, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxolinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, aza Oxalic acid Base, diazepine alkyl, tropanyl, oxazolidinyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.
[0102] "Hydroxyalkyl" means an alkyl group substituted with one or more -OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2CH2-, and CH2-CH(OH)-.
[0103] "Haloalkyl" means an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, and the like.
[0104] "Haloalkoxy" means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, and the like.
[0105] "Cyano" refers to a substituent having a nitrogen atom and a carbon atom connected by a triple bond, for example, C≡N.
[0106] "Amino" means a substituent containing at least one nitrogen atom (eg, NH2).
[0107] "Pomalidomide" or 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione has the following structure:
[0108]
[0109] B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions
[0110] "Prodrug" or "prodrug derivative" means a covalently bonded derivative or carrier of a parent compound or active drug substance that undergoes at least some biotransformation before exhibiting one or more of its pharmacological effects. Generally speaking, such prodrugs have metabolically cleavable groups and are rapidly converted in vivo to produce the parent compound, for example, by hydrolysis in the blood, and generally include ester and amide analogs of the parent compound. Prodrugs are formulated with the goal of improving chemical stability, improving patient acceptance and compliance, improving bioavailability, extending duration of action, improving organ selectivity, improving formulations (e.g., increased water solubility) and / or reducing side effects (e.g., toxicity). Generally speaking, the prodrug itself has weak biological activity or no biological activity and is stable under normal conditions.Prodrugs can be readily prepared from the parent compound using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, in particular Chapter 5: "Design and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, KB Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1996. Burger's Medicinal Chemistry and Drug Discovery, 5th ed., M. Wolff (ed.), John Wiley & Sons, 1995, in particular, volume 1 and pages 172-178 and 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987, each of which is incorporated herein by reference in its entirety.
[0111] As used herein, "pharmaceutically acceptable prodrug" means a prodrug of the compounds of the present disclosure that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and, where possible, effective for its intended use as well as in zwitterionic form.
[0112] "Salt" means an ionic form of a parent compound or the product of the reaction between a parent compound and a suitable acid or base to prepare an acid salt or basic salt of the parent compound. Salts of the compounds of the present disclosure can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, salts are prepared by reacting the free basic or acidic parent compound with a stoichiometric amount or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
[0113] "Pharmaceutically acceptable salts" means salts of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio, are generally water-soluble or oil-soluble or dispersible, and are effective for their intended use. The term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Since the compounds of the present disclosure are useful in both free base form and salt form, in practice, using the salt form is equivalent to using the base form. A list of suitable salts is found, for example, in SM Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety.
[0114] "Pharmaceutically acceptable acid addition salts" means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable and are prepared by reacting with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, etc.) and organic acids (e.g., acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic ... The present invention also includes but is not limited to amino acid, glycolic acid, glycerophosphate, hemisulfuric acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (hydroxyethylsulfonic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, p-aminobenzenesulfonic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, etc.
[0115] "Pharmaceutically acceptable base addition salts" means salts that retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, and are formed with inorganic bases (e.g., ammonia or hydroxides, carbonates, or ammonium bicarbonates) or metal cations (e.g., sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc.). Particularly preferred are ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, quaternary ammonium compounds, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine , caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-diphenylhydroxymethylamine, N,N'-dibenzylethylenediamine, polyamine resins, etc. Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0116] "Solvate" means a complex of variable stoichiometry formed by a solute (e.g., a compound of formula (I)) and a solvent (e.g., water, ethanol, or acetic acid). This physical association may involve varying degrees of ionic and covalent bonds, including hydrogen bonds. In some cases, the solvate is capable of separation (e.g., when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid). Generally, such solvents selected for the purposes of this disclosure do not interfere with the biological activity of the solute. Solvates encompass both solution-phase and separable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
[0117] "Hydrate" means a solvate wherein one or more of the solvent molecules is water.
[0118] The compounds of the present disclosure, as discussed below, include their free bases or acids, their salts, solvates, and prodrugs, and may include oxidized sulfur atoms or quaternized nitrogen atoms in their structures (although not explicitly stated or shown), particularly their pharmaceutically acceptable forms. Such forms (particularly pharmaceutically acceptable forms) are intended to be included in the appended claims.
[0119] C. Isomer Terminology and Conventions
[0120] "Isomers" means compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.
[0121] "Stereoisomer" or "optical isomer" means a stable isomer having at least one chiral atom or restricted rotation resulting in a vertical asymmetric plane (e.g., some biphenyls, allenes, and spiro compounds) and that can rotate plane-polarized light. Because asymmetric centers and other chemical structures are present in the compounds of the present disclosure that can cause stereoisomerism, the present disclosure contemplates stereoisomers and mixtures thereof. The compounds of the present disclosure and their salts include asymmetric carbon atoms and therefore can exist as single stereoisomers, racemates, and mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as racemic mixtures. However, if desired, such compounds can be prepared or separated into stereoisomers, i.e., as individual enantiomers or diastereomers, or as mixtures enriched in stereoisomers. As discussed in more detail below, individual stereoisomers of a compound are prepared by synthesis from optically active starting materials containing the desired chiral center, or by preparing a mixture of enantiomeric products followed by separation or resolution (e.g., conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, use of a chiral resolving agent, or direct separation of the enantiomers on a chiral chromatographic column). Starting compounds of specific stereochemistry are either commercially available or prepared by the methods described below and resolved by techniques well known in the art.
[0122] "Enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of one another.
[0123] "Diastereomers" or "diastereomers" means optical isomers that are not mirror images of one another.
[0124] "Racemic mixture" or "racemate" means a mixture containing equal parts of individual enantiomers.
[0125] "Non-racemic mixture" means a mixture containing unequal parts of individual enantiomers.
[0126] "Geometric isomers" means stable isomers resulting from rotational freedom restrictions in double bonds (e.g., cis-2-butene and trans-2-butene) or ring structures (e.g., cis-1,3-dichlorocyclobutane and trans-1,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, ring structures, etc. can be present in the compounds of the present disclosure, the present disclosure contemplates each of the different stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these ring structures. Substituents and isomers are represented using the cis / trans convention or using the E or Z system, where the term "E" means that higher-order substituents are on opposite sides of the double bond and the term "Z" means that higher-order substituents are on the same side of the double bond. A detailed discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, which is hereby incorporated by reference in its entirety. Several examples below represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of E and Z isomers can be performed by analytical methods, such as X-ray crystallography, 1 H NMR, and 13 C NMR.
[0127] Some compounds of the present disclosure can exist in more than one tautomeric form. As mentioned above, the compounds of the present disclosure include all such tautomers.
[0128] It is well known in the art that the biological and pharmacological activities of compounds are sensitive to the stereochemistry of the compound. Thus, for example, enantiomers typically exhibit significantly different biological activities, including differences in pharmacokinetic properties (including metabolism, protein binding, etc.) and pharmacological properties (including the type of activity displayed, degree of activity, toxicity, etc.). Therefore, it will be understood by those skilled in the art that one enantiomer can be more active or can exhibit a beneficial effect when enriched relative to the other enantiomer or when separated from the other enantiomers. Additionally, those skilled in the art will know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the present disclosure from the knowledge of the present disclosure and the prior art.
[0129] Thus, while the racemic form of a drug can be used, it is generally not as effective as administering an equal amount of the enantiomerically pure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and act merely as a simple diluent. For example, although ibuprofen has previously been administered as a racemate, only the S-isomer of ibuprofen has been found to be effective as an anti-inflammatory agent (however, in the case of ibuprofen, although the R-isomer is inactive, it is converted to the S-isomer in the body, so the racemic form of the drug is less effective than the pure S-isomer). Furthermore, the pharmacological activity of enantiomers can have significantly different biological activities. For example, S-penicillamine is a therapeutic agent for chronic arthritis, while R-penicillamine is toxic. In fact, some purified enantiomers have advantages over the racemate, as it has been reported that purified individual isomers have faster transdermal penetration rates than the racemic mixture. See U.S. Patent Nos. 5,114,946 and 4,818,541.
[0130] Therefore, if one enantiomer is pharmacologically more active, less toxic, or has a more favorable body distribution than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way, the treated patient would be exposed to a lower total dose of the drug and a lower dose of the potentially toxic enantiomer or other enantiomer inhibitors.
[0131] The preparation of pure enantiomers or mixtures having the desired enantiomeric excess (ee) or enantiomeric purity can be accomplished by one or more of a number of methods known to those skilled in the art for (a) separation or resolution of enantiomers, or (b) enantioselective synthesis, or a combination of these methods. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and non-enzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are generally disclosed in: Chiral Separation Techniques: A Practical Approach (2nd ed.), G. Subramanian (ed.), Wiley-VCH, 2000; TE Beesley and RPW Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc., 2000. In addition, there are equally well-known methods for quantifying enantiomeric excess or purity (e.g., GC, HPLC, CE, or NMR) and for identifying absolute configuration and conformation (e.g., CDORD, X-ray crystallography, or NMR).
[0132] In general, all tautomeric and isomeric forms and mixtures of a chemical structure or compound, whether individual geometric isomers or stereoisomers or racemic or non-racemic mixtures, are contemplated unless a specific stereochemistry or isomeric form is explicitly indicated in the compound name or structure.
[0133] D. Drug Administration and Treatment Terminology and Conventions
[0134] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
[0135] "Effective amount" or "therapeutically effective amount," when used in reference to a compound, means an amount of a compound of the present disclosure that (i) treats or prevents a particular disease, condition, or disorder, (ii) reduces, alleviates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.
[0136] The term "pharmaceutically effective amount" or "therapeutically effective amount" means an amount of a compound according to the present disclosure that, when administered to a patient in need thereof, is sufficient to achieve treatment of the disease state, condition, or disorder in which the compound has utility. This amount is sufficient to elicit the biological or medical response of the tissue, system, or patient sought by the researcher or clinician. The amount of a compound according to the present disclosure that constitutes a therapeutically effective amount will vary according to factors such as the compound and its biological activity, the composition for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease state or disorder being treated and its severity, the drugs used in combination or together with the compound of the present disclosure, and the patient's age, weight, general health, sex, and diet. Such a therapeutically effective amount can be routinely determined by those of ordinary skill in the art based on their own knowledge, the prior art, and the present disclosure.
[0137] As used herein, the term "pharmaceutical composition" refers to a compound of the present disclosure, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in a form suitable for oral or parenteral administration, and at least one pharmaceutically acceptable carrier.
[0138] "Carrier" encompasses vehicles, excipients, and diluents, and means a material, composition, or vehicle involved in carrying or transporting a pharmaceutical agent from one organ or part of a subject's body to another, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
[0139] A subject (preferably a human) is "in need of" a treatment if the subject would benefit biologically, medically, or in quality of life from such treatment.
[0140] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to the reduction or suppression of a given condition, symptom or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
[0141] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder refers to alleviating or relieving the disease or disorder (i.e., slowing or arresting the progression of the disease or at least one clinical symptom thereof); or alleviating or improving at least one physical parameter or biomarker associated with the disease or disorder, including those that may not be discernible by the patient.
[0142] As used herein, the terms "prevent," "preventing," or "prevention" of any disease or disorder refers to prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
[0143] "Pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal being treated therewith.
[0144] Unless otherwise indicated, "disorder" is intended to refer to the term disease, condition, or ailment and is used interchangeably with these terms.
[0145] "Administer," "administering," or "administration" means administering a disclosed compound, or a pharmaceutically acceptable salt or composition of a disclosed compound, directly to a subject, or administering a prodrug derivative or analog of a compound, or a pharmaceutically acceptable salt or composition of a compound to a subject, which can form an equivalent amount of the active compound in the subject.
[0146] "Prodrug" means a compound that is convertible in vivo by metabolic means (eg, by hydrolysis) to a disclosed compound.
[0147] "Compounds of the present disclosure," "disclosed compounds," and equivalent expressions (unless expressly stated otherwise) refer to compounds of formula (I), (Ia), and (Ib), as well as compounds (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), (I-10), (I-11), (I-12), (I-13), (I-14), (I-15), (I-16), (I-17), (I-18), (I-24), (I-25), (I-26), (I-27), (I-28), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-35), (I-36), (I-37), (I-38), (I-39), (I-40), (I-41), (I-42), (I-43), (I-44), (I-45), (I-46), (I-47), (I-48), (I-49), (I-50), (I-51), (I-52), (I-53), (I-54), (I-55), (I-56), (I-57), (I-58), (I-59), (I-60), (I-61), (I-62), (I-63), (I-64), (I-65), (I-66), (I-67), (I-68), (I-69), (I-70), (I-71), (I-72), (I-73), (I-74), (I-75), (I-76), (I-77), (I-78), (I-79), (I-80), (I-81), (I-82), (I-83), (I-84 8), (I-29), (I-30), (I-31), (I-32), (I-33), (I-34), (I-34), (I-36), (I-37), and (I-38), as described herein, including their tautomers, prodrugs, salts (particularly pharmaceutically acceptable salts), and solvates and hydrates, where the context permits, as well as all stereoisomers (including diastereomers and enantiomers), rotamers, tautomers and isotopically labeled compounds (including deuterium substitution), as well as inherently formed moieties (e.g., polymorphs, solvates and / or hydrates). For the purposes of this disclosure, solvates and hydrates are generally considered to be compositions. Generally and preferably, the compounds of the present disclosure and formulas representing the compounds of the present disclosure should be understood to include only stable compounds thereof and exclude unstable compounds, even if unstable compounds can be considered to be actually included in the compound formula. Similarly, references to intermediates (whether or not they themselves are claimed) are intended to include their salts and solvates, where the context permits. For clarity, specific instances where the context permits are sometimes indicated in the text, but these are purely illustrative and are not intended to exclude other instances where the context permits.
[0148] By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, compounds with "dangling valencies" or carbanions are not contemplated by the present disclosure.
[0149] In particular embodiments, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.
[0150] The yield for each reaction described herein is expressed as a percentage of the theoretical yield. "Cancer" means any cancer caused by malignant neoplastic cell proliferation, such as a tumor, neoplasm, carcinoma, sarcoma, leukemia, lymphoma, and the like. For example, cancers include, but are not limited to, mesothelioma, leukemia, and lymphoma, such as cutaneous T-cell lymphoma (CTCL), non-cutaneous peripheral T-cell lymphoma, lymphomas associated with human T-cell lymphotropic virus (HTLV) such as adult T-cell leukemia / lymphoma (ATLL), B-cell lymphoma, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, lymphoma and multiple myeloma, non-Hodgkin's lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, Burkitt's lymphoma, adult T-cell leukemia lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. Further examples include myelodysplastic syndrome, solid tumors in children (such as brain tumors, neuroblastoma, retinoblastoma, Wilms' tumor, bone tumors, and soft tissue sarcomas), common solid tumors in adults (such as head and neck cancer (e.g., cancer of the mouth, larynx, and nasopharynx), esophageal cancer, genitourinary cancer (e.g., cancer of the prostate, bladder, kidney, uterus, ovary, testicle), lung cancer (e.g., small cell and non-small cell lung cancer), breast cancer, pancreatic cancer, melanoma, and other skin cancers, gastric cancer, brain tumors, tumors associated with Gorlin's syndrome (e.g., medulloblastoma, meningioma, etc.), and liver cancer. Additional exemplary forms of cancer that can be treated by the subject compounds include, but are not limited to, cancer of skeletal or smooth muscle, gastric cancer, cancer of the small intestine, rectal cancer, cancer of the salivary glands, endometrial cancer, adrenal cancer, anal cancer, rectal cancer, parathyroid cancer, and pituitary cancer.
[0151] Compounds described herein can be used to prevent, treat, and study other cancers such as colon cancer, familial adenomatous polyposis carcinoma, and hereditary non-polyposis colorectal cancer, or melanoma. In addition, cancers include, but are not limited to, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, thyroid cancer (medullary and papillary thyroid cancer), kidney cancer, renal parenchymal cancer, cervical cancer, uterine corpus cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary system cancer, melanoma, brain tumors (such as glioblastoma, astrocytoma, meningioma, medulloblastoma, and peripheral neuroectodermal tumor), gallbladder cancer, bronchogenic carcinoma, multiple myeloma, basal cell carcinoma, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, sarcoma, liposarcoma, fibrosarcoma, Ewing's sarcoma, and plasmacytoma.
[0152] When referring to a method of treatment or therapeutic use of a combination of a compound of Formula (I) or a compound described in Examples 16, 17, or 35, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and one or more second agents, "simultaneously" or "concurrently" means administering the compound and the one or more second agents by the same route and at the same time.
[0153] When referring to a method of treatment or therapeutic use of a combination of a compound of Formula (I) or a compound described in Examples 16, 17, or 35, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agents, "separately" or "separately" means administering the compound and the one or more second agents by different routes and at approximately the same time.
[0154] When referring to the treatment method or therapeutic use of a combination of a compound with formula (I) or the compound described in Examples 16, 17 or 35, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer and one or more second agents, "over a period of time" refers to the administration of the compound and the one or more second agents by the same or different routes and at different times. In some embodiments, the administration of the compound or one or more second agents occurs before the administration of other substances begins. In this way, one of the active ingredients (i.e., a compound with formula (I) or the compound described in Examples 16, 17 or 35, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer, or one or more second agents) can be administered for several months before administering one or more other active ingredients. In this case, simultaneous administration does not occur. Another type of therapeutic administration over a period of time consists of administering two or more active ingredients of the combination over time (using different administration frequencies for each active ingredient) such that at certain time points all of the active ingredients are administered simultaneously, while at other time points only a portion of the active ingredients of the combination may be administered (such as, for example, a compound of Formula (I) or a compound described in Examples 16, 17, or 35, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agents, where therapeutic administration over a period of time can result in the compound of Formula (I) or a compound described in Examples 16, 17, or 35, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, being administered once daily and the one or more second agents being administered once every four weeks).
[0155] "IKZF2-dependent disease or disorder" means any disease or disorder that is directly or indirectly affected by modulation of IKZF2 protein levels.
[0156] "IKZF4-dependent disease or disorder" means any disease or disorder that is directly or indirectly affected by modulation of IKZF4 protein levels.
[0157] D. Specific Examples and Methods for Testing Compounds of Formula (I)
[0158] The present disclosure relates to compounds capable of modulating IKZF2 protein levels, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof (which are useful for treating diseases and disorders associated with modulation of IKZF2 protein levels). The present disclosure further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof (which are useful for reducing or decreasing IKZF2 protein levels).
[0159] In one embodiment, the compound of formula (I) has the structure of formula (Ia):
[0160]
[0161] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
[0162] In another embodiment, the compound of formula (I) has the structure of formula (Ib):
[0163]
[0164] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
[0165] In some embodiments of the above formulae (ie, Formula (I), Formula (Ia), and / or Formula (Ib)),
[0166] R3 is (C1-C6) alkyl, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, or a 4- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to four R4; and the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R5, or
[0167] Each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6'、Halogen、-OH、-NH2、CN、(C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7;
[0168] Each R5 is independently selected from (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -NH2, CN, (C3-C7) cycloalkyl, 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or
[0169] When on adjacent atoms, the two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 Replace, or
[0170] Two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 replace;
[0171] Each R7 is independently selected from (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -C(O)R8, -(CH2) 0-3 C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10 ) aryl, adamantyl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, (C6-C10 )aryl, a monocyclic or bicyclic 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted by one to four R 11 substituted, and the aryl, heteroaryl, and heterocycloalkyl are optionally substituted by one to four substituents each independently selected from the following: halogen, (C1-C6) alkyl, (C1-C6) haloalkyl, and (C1-C6) alkoxy, or
[0172] Two R7 together with the carbon atom to which they are attached form a=(O), or
[0173] When on adjacent atoms, the two R7 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 Replace, or
[0174] Two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 replace;
[0175] Each R 11 Independently selected from CN, (C1-C6) alkoxy, (C6-C 10 )aryl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heterocycloalkyl are optionally substituted with one to four substituents each independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN;
[0176] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0177] In some embodiments of the above formula, R x is D. In another embodiment, R x It’s H.
[0178] In some embodiments of the above formula, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2)0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R1 is -C(O)NH2, -C(O)OH, or CN. In yet another embodiment, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, or halogen. In another embodiment, R1 is -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN. In yet another embodiment, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0- 2NH2, or CN. In another embodiment, R1 is (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, or CN. In yet another embodiment, R1 is (C1-C6)alkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, or CN. In another embodiment, R1 is (C1-C6)alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN. In yet another embodiment, R1 is (C1-C6)alkoxy, halogen, -OH, -NH2, or CN.
[0179] In some embodiments with the above formula, each R2 is independently (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, CN or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, CN or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)hydroxyalkyl, CN or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, CN or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, CN or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl or (C1-C6)haloalkyl.
[0180] In another embodiment, each R2 is independently (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, or halogen. In yet another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)hydroxyalkyl, or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, or halogen. In yet another embodiment, each R2 is independently (C1-C6)alkyl or (C1-C6)haloalkyl. In another embodiment, each R2 is independently (C1-C6)alkyl or halogen. In yet another embodiment, each R2 is independently (C1-C6)alkyl or halogen. In yet another embodiment, each R2 is independently (C1-C6)haloalkyl or halogen. In another embodiment, each R2 is independently (C1-C6)alkyl.
[0181] In some embodiments of the above formula, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 5- or 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 4- or 5-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C4-C7)cycloalkyl group or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C4-C6)cycloalkyl or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S.
[0182] In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C6)cycloalkyl group. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C4-C7)cycloalkyl group. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C5-C7)cycloalkyl group. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C6-C7)cycloalkyl group. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C5-C6)cycloalkyl group. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C4-C6)cycloalkyl group. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C6)cycloalkyl group. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a (C3-C5)cycloalkyl group. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a 5- or 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, R1 and R2, together with the carbon atom to which they are attached, form a 4- or 5-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S.
[0183] In some embodiments of the above formula, two R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, two R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 5- or 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, two R2, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 4- or 5-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, two R2, together with the carbon atom to which they are attached, form a (C4-C7)cycloalkyl group or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a (C4-C6)cycloalkyl or a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S.
[0184] In another embodiment, two R2 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl group. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a (C3-C6)cycloalkyl group. In another embodiment, two R2 together with the carbon atom to which they are attached form a (C4-C7)cycloalkyl group. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a (C5-C7)cycloalkyl group. In another embodiment, two R2 together with the carbon atom to which they are attached form a (C6-C7)cycloalkyl group. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a (C5-C6)cycloalkyl group. In another embodiment, two R2 together with the carbon atom to which they are attached form a (C4-C6)cycloalkyl group. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a (C3-C6)cycloalkyl group. In another embodiment, two R2 together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl group. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a 4- to 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, two R2 together with the carbon atom to which they are attached form a 5- or 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, two R2 together with the carbon atom to which they are attached form a 4- or 5-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S.
[0185] In some embodiments of the above formula, R3 is (C1-C6)alkyl, (C6-C 10 ) aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C8) cycloalkyl, or a 4- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to four R4; and the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R5. In another embodiment, R3 is (C1-C6) alkyl, (C6-C8) cycloalkyl, or a 4- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to four R4; and the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R5. 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to four R4; and the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R5.
[0186] In another embodiment, R3 is (C1-C4)alkyl, (C6-C 10) aryl, (C3-C8) cycloalkyl, or 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R4; and wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In yet another embodiment, R3 is (C1-C4) alkyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, or 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R4; and wherein the heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R3 is (C1-C4) alkyl, (C6-C 10 ) aryl, a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8) cycloalkyl group, wherein the alkyl group is optionally substituted with one to three R4; and wherein the aryl, heteroaryl, and cycloalkyl group are optionally substituted with one to three R5. In another embodiment, R3 is (C1-C4) alkyl, (C6-C8) cycloalkyl, 10 ) aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R4; and wherein the aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one to three R5.
[0187] In another embodiment, R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R3 is (C6-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. 10 In another embodiment, R is phenyl, (C-C) cycloalkyl, or a 5- to 7-membered heterocycloalkyl group comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R is phenyl, (C-C) cycloalkyl, or a 5- to 7-membered heterocycloalkyl group comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R is (C-C) alkyl optionally substituted with one to three R4. In another embodiment, R is (C-C) alkyl substituted with one to three R4.
[0188] In another embodiment, R3 is (C3-C8)cycloalkyl or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to three R5. In yet another embodiment, R3 is (C6-C8)cycloalkyl or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to three R5. 10 ) aryl or a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heteroaryl are optionally substituted with one to three R5. In another embodiment, R3 is (C3-C8) cycloalkyl or (C6-C 10 ) aryl, wherein the cycloalkyl and aryl are optionally substituted by one to three R5. In another embodiment, R3 is a 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, or a 5- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the heteroaryl and heterocycloalkyl are optionally substituted by one to three R5. In another embodiment, R3 is a (C6-C6) aryl, wherein the cycloalkyl and aryl are optionally substituted by one to three R5. In another embodiment, R3 is a (C6-C6) aryl, wherein the cycloalkyl and aryl are optionally substituted by one to three R5. 10 )aryl. In yet another embodiment, R3 is a 5- or 6-membered heteroaryl group comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5. In another embodiment, R3 is a (C3-C8)cycloalkyl group optionally substituted with one to three R5. In yet another embodiment, R3 is a 5- to 7-membered heterocycloalkyl group comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0189] In some embodiments of the above formula, each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6' 、Halogen、-OH、-NH2、CN、(C6-C 10 ) aryl, a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7. In another embodiment, each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6' 、Halogen、-OH、-NH2、CN、(C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7.
[0190] In another embodiment, each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6' , halogen, -OH, -NH2, or CN. In another embodiment, each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' 、-NR6C(O)R 6' , halogen, or -OH. In another embodiment, each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7. In another embodiment, each R4 is independently selected from halogen, -OH, (C6-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S. 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7.
[0191] In another embodiment, each R4 is independently selected from -C(O)OR6, -C(O)NR6R 6' , and -NR6C(O)R 6' In another embodiment, each R4 is independently selected from -C(O)OR6, (C6-C 10 ) aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7. In yet another embodiment, each R4 is independently selected from (C6-C8) 10) aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to four R7. In another embodiment, each R4 is independently selected from (C6-C8) 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0192] In another embodiment, each R4 is independently selected from (C6-C 10 ) aryl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heteroaryl are optionally substituted with one to three R7. In yet another embodiment, each R4 is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heteroaryl are substituted by one to three R7.
[0193] In another embodiment, each R4 is independently selected from (C3-C8)cycloalkyl and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, each R4 is independently selected from (C3-C8)cycloalkyl and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heterocycloalkyl groups are optionally substituted with one to three R7.
[0194] In another embodiment, each R4 is independently (C6-C 10 ) aryl, which is optionally replaced by one to three R 7 .In another embodiment, each R 4 is independently a 5- or 6-membered heteroaryl group comprising 1 to 3 heteroatoms selected from N, O, and S, which is optionally replaced by one to three R 7 .
[0195] In another embodiment, each R4 is optionally by one to three R7 substituted (C3-C8) cycloalkyl.In another embodiment, each R4 is independently 5 yuan to 7 yuan of heterocycloalkyl comprising 1 to 3 heteroatomic atoms selected from O, N and S, optionally by one to three R7 substituted.
[0196] In some embodiments of the above formula, each R5 is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, CN, (C3-C7)cycloalkyl, 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, each R5 is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN. In yet another embodiment, each R5 is independently selected from (C3-C7)cycloalkyl, a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0197] In another embodiment, each R5 is independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, CN, (C3-C7)cycloalkyl, 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0198] In another embodiment, each R is independently selected from (Ci-C6)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, and (Ci-C6)haloalkoxy. In yet another embodiment, each R is independently selected from (Ci-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN. In another embodiment, each R is independently selected from (Ci-C6)alkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkyl, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, and CN.
[0199] In some embodiments of the above formula, when on adjacent atoms, two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 replace.
[0200] In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form a phenyl ring or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In yet another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form a phenyl ring or a 5-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form a phenyl ring or a 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 replace.
[0201] In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form (C6-C 10 ) aryl ring, which is optionally substituted by one to three R 10 In yet another embodiment, when on adjacent atoms, two R5 taken together with the atoms to which they are attached form a group optionally replaced by one to three R 10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10In yet another embodiment, when on adjacent atoms, two R5, together with the atoms to which they are attached, form a 5-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, when on adjacent atoms, two R5 together with the atoms to which they are attached form a 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 replace.
[0202] In some embodiments of the above formula, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 6- or 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 replace.
[0203] In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 5-membered or 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4- to 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 4-membered or 5-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a (C3-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R10 In another embodiment, two R5 together with the atoms to which they are attached form a (C4-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 replace.
[0204] In another embodiment, two R5 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R5. 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C6-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C5-C6)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C4-C6)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C6)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C5)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a (C3-C4)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 replace.
[0205] In another embodiment, two R5 together with the atoms to which they are attached form a 10 In another embodiment, two R5 together with the atoms to which they are attached form a substituted (C3-C7) cycloalkyl ring. 10 In another embodiment, two R5 together with the atoms to which they are attached form a substituted (C4-C7) cycloalkyl ring. 10In yet another embodiment, two R5 together with the atoms to which they are attached form a substituted (C5-C7) cycloalkyl ring. 10 In another embodiment, two R5 together with the atoms to which they are attached form a substituted (C6-C7) cycloalkyl ring. 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a substituted (C3-C6) cycloalkyl ring. 10 In another embodiment, two R5 together with the atoms to which they are attached form a substituted (C3-C5) cycloalkyl ring. 10 Substituted (C3-C4)cycloalkyl ring.
[0206] In another embodiment, two R5 together with the atoms to which they are attached form a 4- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R5. 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a 5- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a 6- or 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In yet another embodiment, two R5 together with the atoms to which they are attached form a 5- or 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a 4- or 5-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 In another embodiment, two R5 together with the atoms to which they are attached form a 4- to 6-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or three R 10 replace.
[0207] In some embodiments of the above formula, R6 is H or (C1-C3) alkyl. In another embodiment, R6 is H or (C6-C 10 In yet another embodiment, R6 is (C1-C3)alkyl or (C6-C 10) aryl. In another embodiment, R6 is H, methyl, ethyl, n-propyl, or isopropyl. In another embodiment, R6 is H, methyl, or ethyl. In yet another embodiment, R6 is H or methyl. In another embodiment, R6 is H.
[0208] In some embodiments having the above formula, R 6' is H or (C1-C3) alkyl. In another embodiment, R 6' is H or (C6-C 10 In yet another embodiment, R 6' is (C1-C3) alkyl or (C6-C 10 In another embodiment, R 6' is H, methyl, ethyl, n-propyl, or isopropyl. In another embodiment, R 6' is H, methyl, or ethyl. In yet another embodiment, R 6' Is H or methyl. In another embodiment, R 6' It’s H.
[0209] In some embodiments of the above formula, each R7 is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -C(O)R8, -(CH2) 0-3 C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10 ) aryl, adamantyl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, (C6-C 10 )aryl, a monocyclic or bicyclic 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted by one to four R 11R7 is substituted, and the aryl, heteroaryl, and heterocycloalkyl are optionally substituted by one to four substituents each independently selected from halogen, (C1-C6) alkyl, (C1-C6) haloalkyl, and (C1-C6) alkoxy. In another embodiment, each R7 is independently selected from (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, -C(O)R8, -(CH2) 0-3 C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10 )aryl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, (C6-C 10 )aryl, a monocyclic or bicyclic 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted by one to four R 11 The aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one to four substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, and (C1-C6)alkoxy.
[0210] In another embodiment, each R7 is independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -C(O)R8, -(CH2) 0-3 C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10 )aryl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, (C6-C10 )aryl, a monocyclic or bicyclic 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted by one to four R 11 The aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one to four substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, and (C1-C6)alkoxy.
[0211] In another embodiment, each R7 is independently selected from -(CH2) 0-3 C(O)OR8, -NR8C(O)OR9, -S(O) p NR8R9, -S(O) p R 12 , (C1-C6) hydroxyalkyl, halogen, -OH, -O(CH2) 1-3 CN, -NH2, CN, -O(CH2) 0-3 (C6-C 10 )aryl, -O(CH2) containing 1 to 3 heteroatoms selected from O, N, and S 0-3 -5-membered or 6-membered heteroaryl, a bicyclic 9-membered or 10-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heteroaryl and heterocycloalkyl are optionally substituted with one or more substituents each independently selected from halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, and (C1-C6)alkoxy.
[0212] In another embodiment, each R7 is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -C(O)R8, -C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, CN, (C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, each R7 is independently selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -C(O)R8, -C(O)OR8, -C(O)NRR9, -NR8C(O)R9, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN.
[0213] In another embodiment, each R is independently selected from (Ci-C6) alkyl, (Ci-C6) alkoxy, (Ci-C6) haloalkyl, (Ci-C6) haloalkoxy, -C(O)R8, -C(O)OR8, -C(O)NRR9, -NR8C(O)R9, (Ci-C6) hydroxyalkyl, halogen, -OH, -NH2, and CN. In yet another embodiment, each R is independently selected from (Ci-C6) alkyl, (Ci-C6) alkoxy, (Ci-C6) haloalkyl, (Ci-C6) haloalkoxy. In another embodiment, each R is independently selected from -C(O)R8, -C(O)OR8, -C(O)NRR9, -NR8C(O)R9, (Ci-C6) hydroxyalkyl, halogen, -OH, -NH2, and CN. In another embodiment, each R7 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, a (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S.
[0214] In another embodiment, each R7 is independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -C(O)R8, -C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, CN, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C7)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S. In yet another embodiment, each R is independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, halogen, -OH, CN, and (C6-C 10 )aryl.
[0215] In some embodiments of the above formula, when on adjacent atoms, two R7 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally replaced by one or more R 10 In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form (C6-C 10 ) aryl ring, which is optionally substituted by one or more R 10 In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or more R 10 In another embodiment, two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring, which is optionally substituted by one or more R 10 In another embodiment, two R7 together with the atoms to which they are attached form a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one or more R 10 replace.
[0216] In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form (C6-C 10 ) aryl ring or a 5-membered or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 or when on adjacent atoms, two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 replace.
[0217] In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring or a 5- to 7-membered heterocycloalkyl ring containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form a (C5-C7)cycloalkyl ring, which is optionally substituted by one to four R 10 In another embodiment, when on adjacent atoms, two R7 together with the atoms to which they are attached form a 5- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to four R 10 replace.
[0218] In some embodiments of the above formula, R8 is H or (C1-C3) alkyl. In another embodiment, R8 is H, methyl, ethyl, n-propyl, or isopropyl. In another embodiment, R8 is H, methyl, or ethyl. In yet another embodiment, R8 is H or methyl. In another embodiment, R8 is H.
[0219] In some embodiments of the above formula, R9 is H or (C1-C3) alkyl. In another embodiment, R9 is H, methyl, ethyl, n-propyl, or isopropyl. In another embodiment, R9 is H, methyl, or ethyl. In yet another embodiment, R9 is H or methyl. In another embodiment, R9 is H.
[0220] In some embodiments having the above formula, each R 10 In another embodiment, each R 10 In another embodiment, each R 10 In another embodiment, each R 10 In another embodiment, each R 10 Independently selected from (C1-C6)alkyl and halogen.
[0221] In some embodiments having the above formula, the two R 10 Together with the carbon atom to which they are attached they form a=(O).
[0222] In some embodiments having the above formula, each R 11 Independently selected from CN, (C1-C6) alkoxy, (C6-C 10 ) aryl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heterocycloalkyl are optionally substituted with one to four substituents each independently selected from (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -NH2, and CN. In another embodiment, each R 11 Independently selected from CN, (C1-C6) alkoxy, (C6-C 10)aryl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heterocycloalkyl are optionally substituted with one to three substituents each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN. In yet another embodiment, each R 11 independently selected from CN, (C1-C6)alkoxy, and (C6-C 10 )aryl, wherein the aryl is optionally substituted with one to three substituents each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN.
[0223] In another embodiment, each R 11 is independently selected from CN, (C1-C6) alkoxy, and a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the heterocycloalkyl group is optionally substituted with one to four substituents each independently selected from (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -NH2, and CN. In another embodiment, each R 11 In another embodiment, each R 11 Independently selected from (C6-C 10 )aryl and a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl and heterocycloalkyl groups are optionally substituted with one to four substituents each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, and CN.
[0224] In some embodiments having the above formula, R 12 (C1-C6) alkyl, (C1-C6) haloalkyl, (C6-C 10 ) aryl, or a 5-membered or 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R 12 is (C1-C6)alkyl, (C1-C6)haloalkyl, or a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R 12is (C1-C4)alkyl, (C1-C4)haloalkyl, phenyl, or a 5-membered or 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0225] In some embodiments of the above formula, n is 0, 1, or 2. In another embodiment, n is 1, 2, or 3. In another embodiment, n is 0 or 1. In yet another embodiment, n is 1 or 2. In another embodiment, n is 2 or 3. In yet another embodiment, n is 0. In yet another embodiment, n is 1. In another embodiment, n is 2. In yet another embodiment, n is 3.
[0226] In some embodiments having the above formula, R x is H, and n is 0. In another embodiment, R x is H, and n is 1. In another embodiment, R x is H, and n is 2.
[0227] In some embodiments having the above formula, R x is H, n is 0, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0228] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0229] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0230] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0231] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0232] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0233] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0234] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7.
[0235] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0236] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0237] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0238] In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0239] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0240] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0241] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0242] In some embodiments having the above formula, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0243] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl.
[0244] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0245] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2)0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0246] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0247] In some embodiments having the above formula, R x is H, n is 1, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2)0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0248] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0249] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0250] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0251] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0252] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0253] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0254] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7.
[0255] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, optionally substituted by one to three R7.
[0256] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0257] In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0258] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0259] In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0260] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0261] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0262] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0263] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0264] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C6-C 10 )aryl.
[0265] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0266] In some embodiments having the above formula, Rx is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0267] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0268] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, -C(O)NH2, -C(O)OH, or CN.
[0269] In some embodiments having the above formula, R x is H, n is 0, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0270] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0271] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0272] In some embodiments having the above formula, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0273] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0274] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0275] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0276] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2)0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7.
[0277] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0278] In some embodiments having the above formula, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0279] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0280] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0281] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, Rx is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0282] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0283] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0284] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl.
[0285] In some embodiments having the above formula, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0286] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0287] In some embodiments having the above formula, R xis H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S, optionally substituted with one to three R5. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0288] In some embodiments having the above formula, R x is H, n is 1, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and each R2 is independently (C1-C6)alkyl. In yet another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0289] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0290] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0291] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0292] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0293] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R xis H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0294] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0295] In some embodiments having the above formula, Rx is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7.
[0296] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0297] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0298] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, Rx is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0299] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0300] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0301] In some embodiments having the above formula, R xis H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0302] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0303] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 )aryl.
[0304] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0305] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0306] In some embodiments having the above formula, R x is H, n is 1, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0307] In some embodiments having the above formula, R x is H, n is 0 or 1, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R xis H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and each R2 is independently (C1-C6)alkyl. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0308] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0309] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R xis H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0310] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0311] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0312] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0313] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0314] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7.
[0315] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0316] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0317] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0318] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0319] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0320] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0321] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group. In another embodiment, R xis H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0322] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 )aryl.
[0323] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0324] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5. x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0325] In some embodiments having the above formula, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5. In another embodiment, R x is H, n is 0 or 1, R1 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0326] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and each R2 is independently (C1-C6)alkyl. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0327] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0- 2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0328] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0329] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0330] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2)0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0331] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R xis H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0332] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0333] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7.
[0334] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2)0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0335] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0336] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0337] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0338] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0339] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0340] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0341] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 )aryl.
[0342] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0343] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0344] In some embodiments having the above formula, R x is H, n is 0, 1, or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0345] In some embodiments having the above formula, R x is H, n is 1 or 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and each R2 is independently (C1-C6)alkyl. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In yet another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0346] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0347] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0348] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2)0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0349] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0350] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0351] In some embodiments having the above formula, R xis H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0352] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2)0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7.
[0353] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0354] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0355] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0356] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0357] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0358] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0359] In some embodiments having the above formula, Rx is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0360] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 )aryl.
[0361] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0362] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2)0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0363] In some embodiments having the above formula, R x is H, n is 1 or 2, R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0364] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and each R2 is independently (C1-C6)alkyl. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In yet another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0365] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0366] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0367] In some embodiments having the above formula, R xis H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0368] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0369] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7. In another embodiment, R xis H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0370] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0371] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7.
[0372] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2)0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl group comprising 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0373] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted with one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0374] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl. R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0375] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0376] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10)aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0377] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0378] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0379] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C6-C6)alkyl optionally substituted with one to three R5 10 )aryl.
[0380] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0381] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0382] In some embodiments having the above formula, R x is H, n is 2, and R1 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, each R2 is independently (C1-C6)alkyl, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0383] In some embodiments having the above formula, R x is H, n is 0, and R1 is (C1-C6)alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0- 2N((C1-C6)alkyl)2, or CN, and R3 is (C1-C6)alkyl optionally substituted with one to three R4. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0384] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0- 2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0385] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0- 2NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0386] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0- 2NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0387] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0388] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0389] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0390] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7. x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7.
[0391] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0392] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0393] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0394] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0395] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0396] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0397] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0398] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C6-C 10 )aryl.
[0399] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0400] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0401] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, -(CH2) 0-2 NH(C1-C6)alkyl, -(CH2) 0-2 N((C1-C6)alkyl)2, or CN, and R3 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0402] In some embodiments having the above formula, R x is H, n is 0, and R1 is (C1-C6)alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0- 2NH2, or CN, and R3 is (C1-C6)alkyl optionally substituted by one to three R4. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0403] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10)aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0404] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted with one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0405] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2NH2, or CN, and R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0406] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0407] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2)0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted by one to three R7.
[0408] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from phenyl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from phenyl and a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl and heteroaryl groups are optionally substituted by one to three R7.
[0409] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is phenyl optionally substituted by one to three R7. x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4, and each R4 is phenyl optionally substituted with one to three R7.
[0410] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0411] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is (C3-C8) cycloalkyl optionally substituted by one to three R7. x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is (C3-C8)cycloalkyl optionally substituted by one to three R7.
[0412] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7. In another embodiment, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R7.
[0413] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2NH2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R5.
[0414] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C6-C 10 )aryl, (C3-C8)cycloalkyl, or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S.
[0415] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, or (C3-C8)cycloalkyl, wherein the aryl, heteroaryl, and cycloalkyl are optionally substituted with one to three R5.
[0416] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C6-C 10 )aryl, a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, or a (C3-C8)cycloalkyl group.
[0417] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is optionally substituted with one to three R5 (C6-C 10 )aryl.
[0418] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0419] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C3-C8)cycloalkyl optionally substituted with one to three R5.
[0420] In some embodiments having the above formula, R x is H, n is 0, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, N, and S, which is optionally substituted with one to three R5.
[0421] In some embodiments having the above formula, R x is H, n is 1, and each R2 is independently (C1-C6)alkyl. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, and R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl optionally substituted by one to three R4. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, and R3 is (C1-C6)alkyl substituted with one to three R4.
[0422] In some embodiments having the above formula, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10)aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is independently selected from -C(O)OR6, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0423] In some embodiments having the above formula, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6)alkyl optionally substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is independently selected from (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0424] In some embodiments having the above formula, R xis H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, (C6-C 10 )aryl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7.
[0425] In some embodiments having the above formula, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2 NH2, or CN, R3 is (C1-C6) alkyl optionally substituted with one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8) cycloalkyl, and 5- to 7-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N, and S, wherein the phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl groups are optionally substituted with one to three R7. In another embodiment, R x is H, n is 1, each R2 is independently (C1-C6) alkyl, R1 is (C1-C6) alkoxy, halogen, -OH, -(CH2) 0-2NH2, or CN, R3 is (C1-C6)alkyl substituted by one to three R4, and each R4 is independently selected from halogen, -OH, phenyl, a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, (C3-C8)cycloalkyl, and a 5- to 7-membered hete...
Claims
1. A compound selected from the group consisting of: 3-(5-(1-benzyl-4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-benzyl-4-methoxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-benzyl-4-fluoropiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 1-Benzyl-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidine-4-carbonitrile; 3-(5-(4-amino-1-benzylpiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(3-Benzyl-3-azabicyclo[4.1.0]hept-6-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(3-(((1r,4r)-4-methoxycyclohexyl)methyl)-3-azabicyclo[4.1.0]hept-6-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(4-fluoro-1-(((1r,4r)-4-methoxycyclohexyl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(4-hydroxy-1-(((1r,4r)-4-methoxycyclohexyl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(4-methoxy-1-(((1r,4r)-4-methoxycyclohexyl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(4-amino-1-(((1r,4r)-4-methoxycyclohexyl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-1-(((1r,4r)-4-methoxycyclohexyl)methyl)piperidine-4-carbonitrile; or a pharmaceutically acceptable salt thereof.
2. A compound selected from: 3-(1-oxo-5-(1-((6-oxo-1,6-dihydropyridin-3-yl)methyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-benzyl-2,6-dimethylpiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; (1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)methyl)cyclohexane-1-carbonitrile; 3-(5-(2,6-dimethylpiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((5-ethoxypyridin-2-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((5-methoxypyridin-2-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((6-methoxypyridin-3-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((6-ethoxypyridin-3-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((5-methyl-1H-imidazol-4-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((4-(fluoromethyl)cyclohexyl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-(2-(1H-pyrazol-1-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-(1-((4-methylpyrimidin-5-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((4-methylcyclohex-3-en-1-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(pyrazin-2-ylmethyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(pyridazin-3-ylmethyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(pyrimidin-4-ylmethyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-((2-methylpyrimidin-5-yl)methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(pyridazin-4-ylmethyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1R,4S)-2-benzyl-2-azabicyclo[2.2.2]octan-5-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1R,5S)-9-benzyl-3-methyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1R,5S)-9-benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1R,5S)-9-benzyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1S,4S)-2-benzyl-2-azabicyclo[2.2.1]hept-5-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((1R,5S)-9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonan-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-(1-(1-ethyl-1H-pyrazol-4-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-(1-(1-ethyl-1H-pyrazol-4-yl)propyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(1-(pyrazin-2-yl)propyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(1-(pyridazin-4-yl)propyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-(6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(1-(4-methoxycyclohexyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(1-(2-(pyridin-4-yl)propan-2-yl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; and 3-(1-oxo-5-(1-((2-oxo-1,2-dihydropyridin-3-yl)methyl)piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione; or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
4. The pharmaceutical composition according to claim 3, further comprising at least one additional pharmaceutical agent.
5. Use of the pharmaceutical composition according to claim 3 or claim 4 in the preparation of a medicament for treating a disease or disorder affected by a reduction in IKZF2 protein levels.
6. Use of the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for degrading IKZF2 in a patient in need thereof.
7. Use of a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing cell proliferation associated with IKZF2 protein levels, wherein cells are contacted with the medicament and the IKZF2 protein level is reduced.
8. Use of a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer associated with IKZF2 protein levels in a patient in need thereof.
9. The use according to claim 8, wherein the cancer associated with IKZF2 protein level is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
10. The use according to claim 8, wherein the cancer associated with IKZF2 protein level is an immune response-deficient cancer or an immunogenic cancer.
11. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt according to claim 1 or 2 in the preparation of a medicament for reducing the level of IKZF2 protein in a subject in need thereof.
12. The use according to any one of claims 6 to 11, wherein the administration of the drug is performed orally, parenterally, subcutaneously, by injection, or by infusion.
13. Use of a compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder affected by a decrease in IKZF2 protein levels.
14. Use of the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease or disorder associated with a decrease in IKZF2 protein levels.
15. The use according to claim 13 or 14, wherein the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).
